Executive Summary for Investors and Strategic Partners
The perception that thrombectomy is “crowded” often stems from evaluating the category in aggregate rather than by addressable sub-markets. For investors and strategic partners, this distinction is critical when assessing where meaningful opportunities still exist.
iCHOR Vascular focuses on two thrombectomy segments where market concentration is high, alternatives have been limited, and workflow innovation is underpenetrated:
- Peripheral arterial thrombectomy (7F)
While frequently grouped into a broad peripheral intervention category, this segment effectively has few if any real incumbent platforms. Differentiation at the workflow and economic level remains constrained—creating space for solutions that can improve efficiency, simplify procedures, or reduce total cost of care. - Deep vein thrombosis (DVT) thrombectomy (14F)
Large-bore venous thrombectomy is often cited as “busy,” yet real-world utilization is concentrated among one or two dominant systems. This concentration reflects high barriers to entry rather than saturation, and it highlights how incremental innovation can still shift share within a relatively narrow competitive field.
In both segments, the opportunity is not driven by expanding the definition of thrombectomy, but by addressing concentrated markets where clinical demand is established and competitive diversity is limited.
For investors, this structure more closely resembles other device categories that appeared mature on the surface but ultimately supported durable platform expansion once differentiation was introduced.
Read the full whitepaper on the “Crowded Thrombectomy Market”
For more information on maximizing peripheral thrombectomy investment opportunities, email us here and an iCHOR team member will get in touch: info@ichorvascular.com
